Outlook Therapeutics Inc
OTLK
查看详细走势图
2.010USD
-0.060-2.90%
收盘 12/19, 16:00（美东）报价延迟15分钟
87.39M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-2.90%
5天
+1.52%
1月
+6.91%
6月
+17.89%
今年开始到现在
+6.35%
1年
+39.58%
查看详细走势图
TradingKey Outlook Therapeutics Inc股票评分
单位: USD 更新时间: 2025-12-19操作建议
Outlook Therapeutics Inc当前公司基本面数据相对健康，增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名178/404位。机构持股占比非常高，近一月多位分析师给出公司评级为持有。最高目标价9.50。中期看，股价处于上升通道。近一个月，市场表现较强，技术面评分较高，但较强的走势得没有得到基本面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Outlook Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
5
位分析师
持有
评级
9.500
目标均价
+375.00%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Outlook Therapeutics Inc亮点
亮点风险
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.
估值合理
公司最新PE估值-1.12，处于3年历史合理位
机构减仓
最新机构持股6.11M股，环比减少59.39%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值1.34M
活跃度增加
近期活跃度增加，过去20天平均换手率0.63
Outlook Therapeutics Inc新闻
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Outlook Therapeutics Inc简介
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.
公司代码OTLK
公司Outlook Therapeutics Inc
CEOJahr (Robert Charles)
网址https://outlooktherapeutics.com/
常见问题
Outlook Therapeutics Inc(OTLK)的当前股价是多少？
Outlook Therapeutics Inc(OTLK)的当前股价是 2.010。
Outlook Therapeutics Inc的股票代码是什么？
Outlook Therapeutics Inc的股票代码是OTLK。
Outlook Therapeutics Inc股票的52周最高点是多少？
Outlook Therapeutics Inc股票的52周最高点是3.390。
Outlook Therapeutics Inc股票的52周最低点是多少？
Outlook Therapeutics Inc股票的52周最低点是0.790。
Outlook Therapeutics Inc的市值是多少？
Outlook Therapeutics Inc的市值是87.39M。
Outlook Therapeutics Inc的净利润是多少？
Outlook Therapeutics Inc的净利润为-75.37M。
现在Outlook Therapeutics Inc(OTLK)的股票是买入、持有还是卖出？
根据分析师评级，Outlook Therapeutics Inc(OTLK)的总体评级为持有，目标价格为9.500。
Outlook Therapeutics Inc(OTLK)股票的每股收益（EPS TTM）是多少
Outlook Therapeutics Inc(OTLK)股票的每股收益（EPS TTM）是-1.790。
相关品种
